Compare Boston Scientific Corporation (BSX) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.61. The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | HYG | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Fixed Income |
52-Week High | $108.14 | $81.32 |
52-Week Low | $42.63 | $78.72 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
HYG trades at $79.52, down 0.24% with a bearish technical outlook indicated by 17 sell signals against 2 buy signals. The ETF maintains dividend distributions, with recent payouts of $0.42 in May 2026 and $0.41 in June 2026. Market sentiment is cautious amid Federal Reserve uncertainty and elevated put volume in high-yield bonds, reflecting investor concerns about interest rate hikes and inflation pressures.
Outlook remains challenged by macroeconomic headwinds and potential Fed tightening, though dividend yield provides income support. Key risks include interest rate volatility and narrowing market breadth. Investors should weigh yield attractiveness against duration risk in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
